Guanfacine Extended-Release (Intuniv) Dosing and Use in Adults with ADHD
Start guanfacine extended-release at 1 mg once daily (morning or evening), titrate by no more than 1 mg weekly to a target range of 1-4 mg/day based on weight-adjusted dosing (0.05-0.12 mg/kg/day), and use as monotherapy only when stimulants are unsuitable, not tolerated, or ineffective—not as first-line treatment. 1
Starting Dose and Administration
Begin with 1 mg once daily, taken either in the morning or evening at the same time each day 1. Evening dosing may be preferable due to the common occurrence of somnolence and fatigue 2. The tablet must be swallowed whole—do not crush, chew, or break it, as this increases the rate of guanfacine release 1. Avoid administration with high-fat meals due to increased drug exposure 1.
Titration Schedule
Increase the dose in increments of no more than 1 mg per week 1. This gradual titration is critical to minimize dose-related adverse effects, particularly hypotension, bradycardia, and sedation 2.
Target Dose Range
The maintenance dose should be 1-4 mg once daily 1. However, weight-adjusted dosing is strongly recommended to balance efficacy and safety:
- Clinically relevant improvements begin at 0.05-0.08 mg/kg once daily
- Doses up to 0.12 mg/kg once daily may provide additional benefit if well tolerated 1
Recent network meta-analysis data from 2026 showed that in children and adolescents, guanfacine reached peak efficacy at approximately 4 mg/day with a U-shaped dose-response curve, suggesting possible reduced efficacy at higher doses with high uncertainty 3. While this study focused on pediatric populations, it underscores the importance of not exceeding 4 mg/day without clear clinical benefit.
Important caveat: Doses above 4 mg/day have not been systematically studied in controlled trials 1. The FDA label explicitly limits the maximum dose to 4 mg/day in standard use.
Monotherapy vs. Adjunctive Use
When to Use as Monotherapy
Guanfacine should be used as monotherapy only when stimulants are not suitable, not tolerated, or have been shown to be ineffective 2. This reflects the European regulatory position and is supported by evidence showing:
- Guanfacine has medium effect sizes, smaller than stimulants 2
- Current guidelines recommend non-stimulants as second-line treatment with stimulants as first-line 2
- Treatment effects are not observed until 2-4 weeks after initiation, unlike stimulants which have rapid onset 2
When to Add to a Stimulant
In the United States, guanfacine is approved as adjunctive therapy to stimulant medications 2. Consider adding guanfacine to a stimulant when:
- Stimulant monotherapy provides suboptimal response despite adequate dosing
- Stimulant-related adverse effects need mitigation, particularly sleep disturbances, elevated blood pressure, or heart rate 2
- Comorbid conditions are present such as tic disorders, Tourette's syndrome, or oppositional behaviors 2
However, evidence in adults is limited. A 2016 double-blind, placebo-controlled study in adults (ages 19-62) with ADHD and suboptimal stimulant response found no significant difference between guanfacine (1-6 mg) and placebo when added to existing stimulant treatment 4. This contrasts with pediatric data showing benefit for adjunctive use.
Monitoring Parameters
Before Initiating Treatment
- Measure baseline heart rate and blood pressure 5, 1
- Obtain personal and family cardiac history, specifically asking about:
- Sudden death
- Cardiovascular symptoms
- Wolff-Parkinson-White syndrome
- Hypertrophic cardiomyopathy
- Long QT syndrome 5
- Consider ECG if cardiac risk factors are present 5
During Treatment
- Monitor heart rate and blood pressure following each dose increase and periodically during maintenance 1
- Assess for sedation, somnolence, and fatigue, which are the most common adverse effects (occurring in >5% of patients) 1
- Watch for hypotension and bradycardia, particularly in patients taking antihypertensives or with cardiovascular disease 1
- Advise patients to avoid dehydration and overheating 1
- Caution against operating heavy equipment or driving until response to medication is known 1
Common Adverse Effects
In monotherapy trials, the most common adverse reactions (≥5% and at least twice placebo rate) were:
- Somnolence
- Fatigue
- Nausea
- Lethargy
- Hypotension 1
Japanese real-world data from 2026 showed that 81% of adults continued guanfacine for 10 weeks, with 52.3% rated as "very much improved" or "much improved" on CGI-I. TEAEs occurred in 55.5% but no serious adverse events were observed 6.
Special Dosing Considerations
Drug Interactions
With Strong CYP3A4 Inhibitors (ketoconazole, clarithromycin, grapefruit juice):
- Limit guanfacine dose to maximum 2 mg/day when initiating with these medications
- Decrease guanfacine dose by half when adding a CYP3A4 inhibitor to existing guanfacine
- Double the guanfacine dose (max 4 mg/day) when discontinuing the CYP3A4 inhibitor, based on tolerability 1
With Strong CYP3A4 Inducers (rifampin, carbamazepine, phenytoin):
- May titrate guanfacine up to 8 mg/day when used with these medications
- Decrease guanfacine dose by half over 1-2 weeks when discontinuing the CYP3A4 inducer (max 4 mg/day) 1
Hepatic or Renal Impairment
Dose reduction may be required in patients with clinically significant hepatic or renal impairment, as guanfacine is primarily metabolized via CYP3A4 and excreted predominantly renally 2, 1.
Discontinuation
Never stop guanfacine abruptly. Taper the dose in decrements of no more than 1 mg every 3-7 days to minimize rebound hypertension 1. Warnings exist for hypotension/bradycardia, somnolence/sedation, and rebound effects upon discontinuation 2.
Missed Doses
When reinitiating after two or more consecutive missed doses, consider retitration based on patient tolerability rather than immediately resuming the previous maintenance dose 1.
Key Clinical Pitfalls
Do not substitute immediate-release guanfacine for extended-release on a mg-per-mg basis—they have different pharmacokinetic profiles with delayed Tmax, reduced Cmax, and lower bioavailability for the extended-release formulation 1
Do not expect rapid symptom improvement—allow 2-4 weeks for treatment effects to emerge 2
Do not use as first-line monotherapy in adults—stimulants remain first-line with stronger evidence 2
Do not overlook cardiovascular monitoring—hypotension and bradycardia are clinically significant risks 2, 1
Be cautious with adjunctive use in adults—the evidence is weaker than in children, with at least one negative RCT 4